


Supplemental Figure 1


Mineral apposition rate for male, female, and OVX HFD mice treated with vehicle or pioglitazone * $= p < 0.05$




Supplementary Figure 2

Mineral apposition rate for male, female, and OVX HFD mice treated with vehicle or sitagliptin *= p<0.05


Trabecular Mineralization Profiles of Male Mice



Trabecular Mineralization Profiles of Female Mice




Trabecular Mineralization Profiles of OVX Mice



Average mineralization profiles for trabecular bone area in sitagliptin- vs. vehicle-treated HFD mice
* = $p < .05$ vehicle vs. sitagliptin


Body weight in *Dpp4*^{+/+} and *Dpp4*^{-/-} mice




Supplementary Figure 4

Body weight in male and female littermate *Dpp4*^{+/+} and *Dpp4*^{-/-} 7 month old mice * = p<.05, DPP-4 WT vs. DPP-4 KO


Trabecular Mineralization Profiles of Male Mice



Trabecular Mineralization Profiles of Female




Trabecular Mineralization Profiles of OVX Female Mice



Average mineralization profiles for trabecular bone area in *Dpp4^{+/+}* and *Dpp4^{-/-}* mice

Supplementary Figure 5



Supplementary Figure 6

Mineral apposition rate in male, female and OVX *Dpp4*^{+/+} (WT) and *Dpp4*^{-/-} (KO) mice